elongation of Candida albicans cells as well as to reduce the percentage of viable cells remaining after phagocytosis. Significant drug-induced anticandidal effects were also observed when peritoneal exudate cells were preincubated with SM-1213 and washed before infection with C. albicans. SM-1213 had no direct anticandidal effect against the yeast or hyphal form of the fungus, suggesting that the observed candidastatic and candidacidal effect of this drug was due to the enhancement of antimicrobial functions of phagocytes.
To expand knowledge of the mechanisms utilized by phagocytes to contain or defepd against microorganisms, research interest has recently developed for a heterogeneous group of chemical compounds that have the capacity to augment the responses of lymphocytes and macrophages. These compounds have been termed "pro-host" (7) because, rather than being directly microbicidal, they enhance the ,antimicrobial activities of host defense cells. Included in such leukocyte-modulating substances are semisynthetic or wholly synthetic agents such as muramyl dipeptide (3, 7) , inosiplex (7) , and levamisole (5, 7) . Another such agent is SM-1Z13, a syn heticJ substituted monosaccharide that is reported to potentiate macrophage bactericidal activity (7) . The enhancing effects of SM-1213 on the fungistatic or fungicidal capacities of guinea pig peritoneal exudate cells (PEC) against both the yeast and hyphal forms of Candida albicans, a clinically important dimorphic fungus (8) , are described in this report.
MATERIALS AND METHODS
Experimental drug. SM-1213 [Therafectin; 1,2-O-isopropylidene-3-0-3 '-(N' ,N'-dimethylamino-n-propyl)-D-glucofuranose, monohydrochloride; P. Gordon (17) , the effect of SM-1213 on intracellular hyphal formation and elongation was measured. In SWA medium alone, 100% of C. albicans cells developed hyphae during the 6-h incubation period. All of the yeast cells phagocytosed by untreated (O ng/ml) macrophages initiated hyphal formation; macrophages treated with SM-1213 (1 ng/ml) reduced the percentage of hyphae formed to 92% (P < 0.05). Hyphae were formed by 82% of fungi within untreated PMNs, and hyphal formation was reduced to 66% within PMNs treated with 1 to 10 ng of SM-1213 per ml (P < 0.01). In addition, of those yeast cells that initiated hyphal formation, the average hyphal length attained after 6 h of incubation was shorter in drug-treated than in untreated (control) PEC (Table 1 ). This effect was most pronounced at the 1 ng/ml drug level, a concentration at which no direct anticandidal effects were observed in the absence of PEC. No significant drug-induced differences in hyphal length were observed at any drug concentration tested after incubation for less than 6 h ( Table  1) . Hyphal elongation within untreated or drug-treated PMNs at 6 h was inhibited to a significantly greater extent (P bCandidal viability was determined in PEC-free samples by the methylene blue dye exclusion technique (12) . < 0.001) than that within macrophages (Table 1) under identical test conditions. Also, hyphae within PMNs treated with 1 ng of SM-1213 per ml were observed to show signs of cellular disintegration by phase-contrast microscopy at the 6-h time interval.
Although hyphal formation was initiated intracellularly, the majority of viable hyphae within untreated and drugtreated macrophages appeared by phase-contrast microscopy to penetrate the phagocyte cell membrane by 6 h and to grow into the extracellular medium. In these instances, then, inhibition of hyphal elongation was not solely intracellular, although the mechanisms of growth inhibition may have been initiated while hyphae were contained wholly within macrophages.
Effect of SM-1213 on the killing of phagocytosed C. albicans cells. Although the majority of C. albicans yeast cells phagocytosed by PEC could initiate hyphal formation, some hyphae were eventually killed by the candidacidal action of the phagocytic cells. After incubation for 6 h, untreated (O ng/ml) macrophages killed 22% of intracellular fungi, whereas treatment of macrophages with 0.1 or 1 ng/ml of drug enhanced killing to 35.5% (P < 0.05) or 46% (P < 0.001), respectively ( Table 2) . Untreated (O ng/ml) PMNs killed 43% of intracellular C. albicans cells, and PMNs treated with 1 ng of SM-1213 per ml killed 62.5% of the intracellular fungus (P < 0.01). Untreated PMNs killed significantly greater percentages of fungi (P < 0.001) than did untreated macrophages ( Table 2) ; treatment of macrophages with 1 ng of SM-1213 per ml enhanced candidal killing by macrophages to the level observed for untreated PMNs (Table 2) .
Although PEC treated with 10 to 100 ng of SM-1213 per ml did not kill a significantly greater percentage of intracellular fungi than untreated PEC (Table 2) , fungal injury was suggested by some reduction in average hyphal length observed for these groups ( Table 1) .
Effect of SM-1213 preincubation of PEC on hyphal elongation of phagocytosed C. albicans cells. The results presented thus far suggest that SM-1213 potentiated one or more intracellular candidacidal processes expressed by PEC. If such potentiation occurs via the modulation of the PEC themselves and not via a direct effect on C. albicans cells, then preincubation of PEC with SM-1213 before infection with fungi should yield similar drug-induced anticandidal effects. To test this hypothesis, after 6 h of preincubation with SM-1213, macrophages were washed to remove residual drug, infected with yeast-phase C. albicans cells, incubated for 2 h, and assessed for intracellular hyphal growth. Significant inhibition of intracellular hyphal elongation occurred in macrophages preincubated with drug at all concentrations tested, relative to untreated macrophages ( Table 3) .
Effect of SM-1213 preincubation of PEC on the killing of phagocytosed C. albicans cells. Macrophages preincubated in culture for 6 h before infection with yeast cells, but otherwise untreated (0 ng/ml), killed 16.5% of intracellular C. albicans cells during the subsequent 2-h infection period (Table 3 ). In comparison, macrophages preincubated with SM-1213 for 6 h killed a significantly greater percentage of intracellular fungi (30 to 36.5%) after 2 h at all drug concentrations tested (Table 3) . In all but the 10 ng/ml treatment group, preincubated macrophages killed an equal or somewhat lower percentage of intracellular fungi than did macrophages incubated with drug from the time of infection (Tables 2 and 3 ). However, killing of C. albicans within preincubated macrophages was substantial, since Candida cells were exposed to macrophages for only a 2-h infection period relative to a 6-h infection period for macrophages incubated simultaneously with Candida cells and drug. DISCUSSION When PEC were infected and incubated with SM-1213, the most significant drug-induced reductions in hyphal growth and candidal viability occurred at the 1 ng/ml drug level (Tables 1 and 2 ). Higher or lower concentrations of drug were less effective, reflecting the bell-shaped dose-response curve frequently observed for immunomodulatory drugs (6, 7) . Others (D. L. Cahall and R. Conklin, Program Abstr. Intersci. Conf. Antimicrob. Agents Chemother. 20th, New Orleans, La., abstr. no. 81, 1980) have reported that SM-1213 enhanced the effectiveness of mouse peritoneal macrophages to inhibit the intracellular multiplication of Mycobacterium tuberculosis bacilli when macrophages were treated in vitro with drug concentrations as low as 0.01 ng/ml and as high as 100 ng/ml; the most effective macrophage-potentiating drug concentration proved to be 1 ng/ml.
It is not surprising that macrophages preincubated with SM-1213 were equally receptive to modification by all levels of drug (Table 3 ) rather than by one or two levels, as observed for nonpreincubated PEC (Tables 1 and 2 (10, 15) . Therefore, SM-1213 has the added capacity to enhance the candidacidal action of macrophages when administered at the time of phagocyte infection. In addition, muramyl dipeptide does not enhance the antimicrobial oxidative functions of PMN (10), whereas SM-1213 at 1 ng/ml was found to promote the candidacidal activity of PMNs as well as of macrophages (Table 2) .
After 6 h of preincubation, only a 2-h incubation period was required for PEC to kill percentages of C. albicans cells almost as great as, or greater than, PEC incubated with fungi for 6 h (Tables 2 and 3 ). This suggests that, once PEC are primed by preincubation in culture for 6 h, they become more effectively candidacidal upon presentation of the infecting microorganism.
The occurrence of maximal drug-induced effects at 6 h for PEC treated with SM-1213 suggested that modulation of PEC anticandidal mechanisms were either initiated at an earlier time interval but enacted slowly (over 6 h), or were not initiated until 6 h. Oxidative killing mechanisms mediated by the production of hydrogen peroxide (H202) and superoxide anion (02) by phagocytes have been implicated in the candidacidal activity of macrophages (16) and PMNs (11, 13) in culture. Others have suggested that a small but sustained oxidative attack by phagocytes results in effective target cell injury and death over time (14, 16) . Since SM-1213 treatment effectively enhances PEC H202 and 02 production at 2 h as well as at 6 h (manuscript in preparation), these data suggest that SM-1213 can enhance the oxidative activities of PEC after only 2 h of drug treatment, and that sustained oxidative injury may be responsible for the observed candidastatic and candidacidal effects at 6 h.
In the studies reported here, PMNs were better able to inhibit intracellular hyphal elongation and to increase intracellular killing of C. albicans than were macrophages. However, the fungicidal capacity of macrophages may have been reduced, since paraffin oil, used as an inducing agent, has been shown to diminish the fungicidal capabilities of these cells in culture (2) . On the other hand, treatment with 1 ng of SM-1213 per ml enhanced the candidacidal capacity of macrophages to the level of untreated PMNs (Table 2) . Appropriate drug treatment also suppressed the formation of hyphae in both macrophages and PMNs, suggesting that SM-1213 contributes to the reduction of hyphal invasiveness into tissues, thereby circumscribing candidal infection. Although the majority of phagocytosed fungi could form hyphae at some point during the 6-h incubation period, some hyphae were nonetheless killed by the action of phagocytes.
In conclusion, SM-1213 is a nonpyrogenic, alkylaminoalkyl substituted monosaccharide of low toxicity (8), in contrast to the alanylisoglutamyl peptide substituted monosaccharide muramyl dipeptide (3). The enhancement of anticandidal functions of both macrophages and PMNs by SM-1213 make it a useful tool for the examination of mechanisms whereby phagocytes interact with and kill microorganisms. Recent studies indicate that this drug can increase the generation of reactive oxygen intermediates by phagocytes (manuscript in preparation), which would provide, in part, an explanation for the observed enhancement of candidacidal capabilities of SM-1213-treated phagocytes.
